The current P/B premium suggests the market is pricing in the value of Aflac's long-duration Japanese book and its stable, recurring premium flows, rather than near-term earnings momentum. However, the persistent discount to Globe Life's 2.31 P/B indicates that investors may be applying a meaningful discount for Aflac's complex currency exposure and operational volatility. The valuation appears to be anchored more on the company's fortress-like balance sheet and dividend sustainability than on a robust growth or profitability outlook.

This extreme volatility, where the loss ratio can spike over 40 percentage points between quarters, is atypical for a supplemental insurer with relatively predictable claim patterns. It implies that management may be using prior-period reserve releases to offset weak current-period results, a practice that obscures the true cost of risk. Investors should monitor for a stabilization of the combined ratio in the 60-65% range as a signal of sustainable underwriting health.

The dramatic ROE swings, particularly the collapse to near-zero in 2025Q1 followed by a rebound, indicate that reported profitability is not being driven by a consistent underwriting or investment thesis. This volatility makes it difficult to assess the company's true return on equity from core operations. The current ROE trajectory suggests that investment yield on float, rather than underwriting profit, may be the primary, but unstable, driver of shareholder returns in recent periods.

Comparing Aflac to its more direct U.S. peer Unum highlights a valuation disconnect. Unum's lower P/E (20.32 vs. 16.99 for Aflac) and higher net margin (5.7%) contrast with Aflac's volatile earnings profile, yet Aflac commands a much higher P/B. This premium appears attributable entirely to the market's valuation of Aflac's Japanese block of business and its unique distribution moat, rather than any operational superiority in the U.S. supplemental market.